Pharmaceutical-grade pre-miR-29 purification using an agmatine monolithic support

Patrícia Pereira1, Ângela Sousa1, João A Queiroz1

  • 1CICS - Health Sciences Research Centre, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal.

Insights

This study introduces a novel affinity chromatography method using monolithic columns for efficient pre-microRNA-29 purification. This advancement offers high purity and yield, crucial for therapeutic microRNA applications.

Area of Science:

  • Biochemistry
  • Chromatography
  • Molecular Biology

Background:

  • MicroRNA-based therapeutics require high-purity microRNA (miRNA) for clinical applications.
  • Pre-microRNA-29 (pre-miR-29) is implicated in various diseases, making its purification critical.
  • Conventional particle-based columns face limitations in miRNA purification.

Purpose of the Study:

  • To develop a novel, efficient, and selective method for purifying pre-miR-29.
  • To utilize monolithic columns combined with agmatine ligands for specific miRNA capture.
  • To optimize purification strategies for high yield and purity of pre-miR-29.

Main Methods:

  • Development of an affinity chromatography method using agmatine-functionalized monolithic columns.
  • Evaluation of flow rates and RNA concentrations on binding capacity.
  • Implementation of stepwise gradients (NaCl, arginine, ammonium sulfate) for binding and elution.
  • Quality control analysis for impurities (proteins, endotoxins, sRNA).

Main Results:

  • The novel method efficiently purifies pre-miR-29 from other small RNA species and bacterial impurities.
  • Dynamic binding capacity is dependent on feed RNA concentration.
  • Elution strategies using sodium chloride or arginine yielded high pre-miR-29 purity (up to 90.11%) and yield (up to 97.33%).
  • Final product exhibited negligible levels of impurities.

Conclusions:

  • Agmatine-based monolithic affinity chromatography is a powerful tool for pre-miR-29 purification.
  • This method provides a rapid, economical, and efficient platform for miRNA purification for clinical use.
  • The developed technique addresses the need for high-quality, biologically active miRNAs in therapeutic development.